(Q38909086)

English

Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28291584%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28291584%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

malignant pleural mesothelioma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Armando Santoro

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28291584%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

object named as

Juanita Lopez

2

1 reference

ORCID Public Data File 2021

author name string

Evan W Alley

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28291584%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Anne Morosky

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28291584%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Sanatan Saraf

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28291584%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Bilal Piperdi

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28291584%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Emilie van Brummelen

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28291584%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

publication date

11 March 2017

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28291584%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28291584%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28291584%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28291584%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

623-630

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28291584%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930169-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Pathology of mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930169-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Malignant pleural mesothelioma: a population-based study of survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930169-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930169-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930169-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930169-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930169-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930169-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930169-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930169-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930169-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The blockade of immune checkpoints in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930169-9

7 January 2021

based on heuristic

inferred from DOI database lookup

FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930169-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930169-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Pembrolizumab for the treatment of non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930169-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930169-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930169-9

7 January 2021

based on heuristic

inferred from DOI database lookup

B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930169-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Development of a Companion Diagnostic for Pembrolizumab in Non-Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930169-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930169-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930169-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930169-9

7 January 2021

based on heuristic

inferred from DOI database lookup

LBA34PEMBROLIZUMAB (PEMBRO; MK-3475) FOR ADVANCED MELANOMA (MEL): RANDOMIZED COMPARISON OF TWO DOSING SCHEDULES

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930169-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930169-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930169-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930169-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiangiogenic therapies for malignant pleural mesothelioma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930169-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930169-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(17)30169-9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28291584%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28291584%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38909086&oldid=1582516234"